Novartis promises blockbuster results from R&D, and soon

Fourteen blockbusters over the next 5 years. Sound ambitious? Novartis ($NVS) thinks it can deliver--and today it's making the case that it can. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.